Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Toxicity
69%
Irinotecan
51%
Drug
48%
Malignant Neoplasm
42%
Docetaxel
34%
Paclitaxel
34%
Neoplasm
28%
Tamoxifen
27%
Therapeutic Drug Monitoring
26%
Cisplatin
24%
Adverse Event
20%
Overall Survival
19%
CYP3A4
18%
Chemotherapy
17%
Sorafenib
16%
Non Small Cell Lung Cancer
15%
Imatinib
15%
Pharmacodynamics
15%
Pemetrexed
14%
Diseases
14%
Breast Cancer
14%
Anticarcinogen
13%
Solid Malignant Neoplasm
13%
Erythromycin
13%
Progression Free Survival
13%
Phosphotransferase Inhibitor
12%
Endoxifen
12%
Gastrointestinal Stromal Tumor
12%
Sunitinib
11%
Immune Checkpoint Inhibitor
11%
Active Metabolite
11%
Cabazitaxel
11%
Neutropenia
11%
Erlotinib
11%
CYP2D6
11%
Fluoropyrimidine
10%
Protein Tyrosine Kinase Inhibitor
10%
Fluorouracil
10%
Enzyme
9%
Duragesic
9%
Capecitabine
9%
Biological Marker
9%
Monotherapy
8%
Melanoma
8%
Nivolumab
8%
Esomeprazole
8%
Androgen Receptor
8%
Drug-Drug Interaction
7%
Regorafenib
7%
Biochemistry, Genetics and Molecular Biology
Overall Survival
22%
Pharmacokinetics
21%
Single-Nucleotide Polymorphism
20%
Association
16%
Progression Free Survival
16%
Sample
15%
Nested Gene
13%
Genotyping
13%
Dose
12%
Accuracy
12%
CYP2D6
11%
Sunitinib
10%
Allele
10%
Kinase
10%
Mutation
9%
CYP3A4
9%
Small Molecule
8%
Metabolic Pathway
8%
Electric Potential
8%
Pharmacogenetics
8%
Time
7%
Phenotype
7%
Development
7%
Blood Level
7%
Cisplatin
6%
CYP3A5
6%
Midazolam
6%
Collagen
6%
Afatinib
6%
Lysozyme
5%
Solution and Solubility
5%
Imatinib
5%
Germline
5%
Erlotinib
5%
Survival
5%
Medicine and Dentistry
Patient
85%
Therapeutic Procedure
37%
Inpatient
19%
Overall Survival
16%
Toxicity
15%
Neoplasm
15%
Combination Therapy
14%
Gastrointestinal Stromal Tumor
14%
Progression Free Survival
13%
Chemotherapy
10%
Immune Checkpoint Inhibitor
9%
Malignant Neoplasm
9%
Analysis
8%
Non Small Cell Lung Cancer
8%
T Cell
7%
Diseases
6%
Pharmacokinetics
6%
Lung Cancer
6%
Irinotecan
5%
Nivolumab
5%
Biological Marker
5%
Serum
5%
Pemetrexed
5%
Cells
5%
Plasma
5%